Company name: Nanordica Medica
EU Contribution: € 2 402 750
Location: Estonia
Around 100 million people worldwide suffer from chronic wounds that won’t heal. Diabetic foot ulcers are among the most difficult to treat. Nanordica Medical develops first-in-class wound care products for faster healing of chronic wounds. Its patented and trademark-protected PREMOTIV® nanotechnology is designed to prevent infection and support healing, enabling 2x faster healing compared to the market leader, according to a recently published clinical study.
Vision & ImpactNanordica Medical's mission and vision: We improve wound management, reduce healthcare costs, and help hundreds of millions of people with wounds by developing innovative PREMOTIV® nanotechnology-based products that prevent infection and promote wound closure simultaneously.
CollaborationThis was a very smooth collaboration, and we received a lot of support from our Project Officer. With EIC support, we have conducted one of the largest clinical trials in diabetic foot ulcers, are approaching regulatory approval and were able to raise our first venture capital round.
What's next ?We have received ISO 13485 certification and have submitted regulatory documentation for CE marking in the EU and FDA 510(k) approval in the US. Upon receiving these approvals, we plan to launch first in four key markets: Germany, the UK, the US and the Baltic States.
In health tech, clinical validation and regulatory approval create a well-known “valley of death,” where grants typically support early R&D while private investors tend to engage much later. For Nanordica Medical, EIC funding was essential in bridging this gap, validating our technology, and enabling our transition from research to commercial readiness. With EIC support, we have conducted one of the largest clinical trials in diabetic foot ulcers, are approaching regulatory approval and were able to raise our first venture capital round. This would have been very difficult to achieve otherwise.